Cargando…
Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis
The aim of this study was to investigate the pathogenesis of combination ipilimumab and nivolumab‐associated colitis (IN‐COL) by measuring gut‐derived and peripheral blood mononuclear cell (GMNC; PBMC) profiles. We studied GMNC and PBMC from patients with IN‐COL, IN‐treated with no adverse‐events (I...
Autores principales: | Sasson, S. C., Zaunders, J. J., Nahar, K., Munier, C. M. L., Fairfax, B. P., Olsson‐Brown, A., Jolly, C., Read, S. A., Ahlenstiel, G., Palendira, U., Scolyer, R. A., Carlino, M. S., Payne, M. J., Cheung, V. T. F., Gupta, T., Klenerman, P., Long, G. V., Brain, O., Menzies, A. M., Kelleher, A. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670140/ https://www.ncbi.nlm.nih.gov/pubmed/32734627 http://dx.doi.org/10.1111/cei.13502 |
Ejemplares similares
-
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020) -
Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
por: Anson, David, et al.
Publicado: (2019) -
Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
por: Moein, Hamid-Reza, et al.
Publicado: (2021) -
Infectious Colitis Associated With Ipilimumab Therapy
por: McCutcheon, Jessica L., et al.
Publicado: (2014) -
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)